摘要
目的：探讨血清糖类相关抗原19-9（CA19-9）对消化系统恶性梗阻性黄疸的临床诊断价值，为该类疾病的临床诊治提供参考。方法以本院2010年5月～2013年7月收治的168例梗阻性黄疸患者为研究对象，对各类梗阻患者血清中的CA19-9水平及临床诊断率进行统计分析。结果胆系结石和硬化性胆管炎致梗阻性黄疸患者治疗后血清CA19-9水平均显著低于治疗前，差异有统计学意义（P＜0.01）；而胆管癌、胰腺癌、十二指肠壶腹癌和肝细胞癌致梗阻性黄疸患者治疗后血清CA19-9水平与治疗前比较，差异无统计学意义（P＞0.05）。 CA19-9在恶性梗阻性黄疸的诊断中，对胆管癌和胰腺癌的诊断灵敏度、特异度、阳性预测值等较高。结论血清CA19-9对于区别梗阻性黄疸良恶性及诊断胆管癌和胰腺癌表现出较高的临床价值。
Objective To investigate the clinical value of serum carbohydrate-associated antigen 19-9 （CA19-9） for the diagnosis of digestive malignant obstructive jaundice,expect to provide a reference for the diagnosis of the diseases. Methods 168 cases of patients with obstructive jaundice treated in our hospital from May 2010 to July 2013 were se-lected,the levels of CA19-9 and diagnosis rate of different patients with obstructive jaundice were analyzed. Results The serum CA19-9 of biliary stones and sclerosing cholangitis patients with obstructive jaundice after treatment were lower than those before treatment,the difference was significant （P＆lt;0.01）;while the serum CA19-9 of bile duct,pancreas, duodenum pot abdominal cancer and hepatocellular carcinoma after treatment compared with before treatment,the dif-ference was not significant （P＆gt;0.05）.CA19-9 had a high sensitivity,specificity,positive predictive value for cholangiocar-cinoma and pancreatic cancer. Conclusion CA19-9 has a definite clinical value for the diagnosis of benign jaundice and malignant jaundice,and benefit to the diagnosis of cholangiocarcinoma and pancreatic cancer.
出处
《中国当代医药》
2014年第31期31-33,共3页
China Modern Medicine
基金
江苏省卫生厅医学科研招标项目(H201323)
